Kenji Yamamoto

Kenji Yamamoto

Auto-generated profile, based on publicly available information

Kenji Yamamoto

Clinical Research Center and Department of Neurology, Utano National Hospital, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in The Lancet Neurology
Verified
Journal Article
Closed access
MTMasayuki Tahara
Masayuki Tahara
TOTomoko Oeda
Tomoko Oeda
KOKazumasa Okada
Kazumasa Okada
TKTakao Kiriyama
Takao Kiriyama
KOKazuhide Ochi
Kazuhide Ochi
HSHideyuki Sawada
Hideyuki Sawada

16 July 2003 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
Carlo SalaCarlo Sala
Carlo Sala
KFKensuke Futai
Kensuke Futai
KYKenji Yamamoto
Kenji Yamamoto
PWPaul F. Worley
Paul F. Worley
YHYasunori Hayashi
Yasunori Hayashi
MSMorgan Sheng
Morgan Sheng
The postsynaptic density (PSD) proteins Shank and Homer cooperate to induce the maturation and enlargement of dendritic spines (Sala et al., 2001). Homer1a is an activity-inducible short-splice variant of Homer that lacks dimerization capacity. Here, we show that Homer1a reduces the density and size of dendritic spines in cultured hippocampal neurons in correlation with an inhibition of Shank targeting to synapses. Expression of Homer1a also decreases the size of PSD-95 clusters, the number of NMDA receptor clusters, and the level of surface AMPA receptors, implying a negative effect on the growth of synapses. In parallel with the morphological effects on synapses, Homer1a-expressing neurons show diminished AMPA and NMDA receptor postsynaptic currents. All of these outcomes required the integrity of the Ena/VASP Homology 1 domain of Homer1a that mediates binding to the PPXXF motif in Shank and other binding partners. Overexpression of the C-terminal region of Shank containing the Homer binding site causes effects similar to those of Homer1a. These data indicate that an association between Shank and the constitutively expressed long-splice variants of Homer (e.g., Homer1b/c) is important for maintaining dendritic-spine structure and synaptic function. Because Homer1a expression is induced by synaptic activity, our results suggest that this splice variant of Homer operates in a negative feedback loop to regulate the structure and function of synapses in an activity-dependent manner.

31 December 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HSHideyuki Sawada
Hideyuki Sawada
TOTomoko Oeda
Tomoko Oeda
SKSadako Kuno
Sadako Kuno
MNMasahiro Nomoto
Masahiro Nomoto
KYKenji Yamamoto
Kenji Yamamoto
FGfor the Amantadine Study Group
for the Amantadine Study Group
Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson's disease. The purpose of the present study was to investigate the efficacy of amantadine in Parkinson's disease patients suffering from dyskinesias. In this multi-center, double-blind, randomized, placebo-controlled, cross-over trial, 36 patients with Parkinson's disease and dyskinesias were randomized, and 62 interventions, which included amantadine (300 mg /day) or placebo treatment for 27 days, were analyzed. At 15 days after washout, the treatments were crossed over. The primary outcome measure was the changes in the Rush Dyskinesia Rating Scale (RDRS) during each treatment period. The secondary outcome measures were changes in the Unified Parkinson's Disease Rating Scale part IVa (UPDRS-IVa, dyskinesias), part IVb (motor fluctuations), and part III (motor function). RDRS improved in 64% and 16% of patients treated with amantadine or placebo, respectively, with significant differences between treatments. The adjusted odds-ratio for improvement by amantadine was 6.7 (95% confidence interval, 1.4 to 31.5). UPDRS-IVa was improved to a significantly greater degree in amantadine-treated patients [mean (SD) of 1.83 (1.56)] compared with placebo-treated patients [0.03 (1.51)]. However, there were no significant effects on UPDRS-IVb or III scores. Results from the present study demonstrated that amantadine exhibited efficacious effects against dyskinesias in 60–70% of patients. UMIN Clinical Trial Registry UMIN000000780

14 January 2009 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
HSHideyuki Sawada
Hideyuki Sawada
TOT. Oeda
T. Oeda
KYK. Yamamoto
K. Yamamoto
NKN. Kitagawa
N. Kitagawa
EME. Mizuta
E. Mizuta
TKT. Kawamura
T. Kawamura

3 August 2011 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
KYKenji Yamamoto
Kenji Yamamoto
YUYoshifumi Ueta
Yoshifumi Ueta
LWLi Wang
Li Wang
RYRyo Yamamoto
Ryo Yamamoto
NINaoko Inoue
Naoko Inoue
NKNobuo Kato
Nobuo Kato
It is proposed that intracellular amyloid-β (Aβ), before extracellular plaque formation, triggers cognitive deficits in Alzheimer disease (AD). Here we report how intracellular Aβ affects neuronal properties. This was done by injecting Aβ protein into rat and mouse neocortical pyramidal cells through whole-cell patch pipettes and by using 3xTg AD model mice, in which intracellular Aβ is accumulated innately. In rats, intracellular application of a mixed Aβ1-42preparation containing both oligomers and monomers, but not a monomeric preparation of Aβ1-40, broadened spike width and augmented Ca2+influx via voltage-dependent Ca2+channels in neocortical neurons. Both effects were mimicked and occluded by charybdotoxin, a blocker of large-conductance Ca2+-activated K+(BK) channels, and blocked by isopimaric acid, a BK channel opener. Surprisingly, augmented Ca2+influx was caused by elongated spike duration, but not attributable to direct Ca2+channel modulation by Aβ1-42. The Aβ1-42-induced spike broadening was blocked by electroconvulsive shock (ECS), which we previously showed to facilitate BK channel opening via expression of the scaffold protein Homer1a. In young 3xTg and wild mice, we confirmed spike broadening by Aβ1-42, which was again mimicked and occluded by charybdotoxin and blocked by ECS. In Homer1a knock-out mice, ECS failed to block the Aβ1-42effect. Single-channel recording on BK channels supported these results. These findings suggest that the suppression of BK channels by intracellular Aβ1-42is a possible key mechanism for early dysfunction in the AD brain, which may be counteracted by activity-dependent expression of Homer1a.

28 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HSHideyuki Sawada
Hideyuki Sawada
TOTomoko Oeda
Tomoko Oeda
AUAtsushi Umemura
Atsushi Umemura
STSatoshi Tomita
Satoshi Tomita
MKMasayuki Kohsaka
Masayuki Kohsaka
HSHiroshi Sugiyama
Hiroshi Sugiyama
C-reactive protein (CRP) is a biomarker of inflammation, and high levels of CRP correlate with vascular death. Chronic inflammation is considered to be involved in neurodegeneration, although there is no evidence linking it with the process of neurodegenerative diseases. To determine the role of baseline CRP levels in the prognosis of patients with Parkinson disease (PD). A cohort of 313 patients with a mean age of 69.1 and mean PD duration of 7.9 years was retrospectively followed for a mean observation time of 1,753 days. CRP was measured when patients were not diagnosed with any infections, and levels were repetitively measured to investigate a tendency of “regression to mean.” The primary outcome measure was a survival time from study enrollment to death. During the observation period 56 patients died. Baseline CRP was log-linearly associated with a risk of death in PD. Mean survival time was 3,149 (95% confidence interval; 3,009-3,289) days in patients with CRP ≤ 0.8mg/L (lower two thirds) and 2,620 (2,343-2,897) days in those with CRP > 0.8 mg/L (top third, p < 0.001, log-rank test). The adjusted hazard ratio (HR) per two-fold higher CRP concentration for all deaths was 1.29 (1.10-1.52), and after excluding PD-unrelated deaths, such as cancer or stroke, HR was 1.23 (1.01-1.49) (adjusted for age, sex, PD duration, modified Hohen-Yahr stages, MMSE scores, and serum albumin). Baseline CRP concentrations were associated with the risk of death and predicted life prognosis of patients with PD. The associations were independent from PD duration, PD severity, cognitive function, ages, and nutritional conditions, suggesting the possibility that subclinical chronic inflammation is associated with a neurodegenerative process in PD.